切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2010, Vol. 04 ›› Issue (04) : 323 -327. doi: 10.3877/cma.j.issn.1674-0793.2010.04.008

所属专题: 文献

论著

VEGF和MVD在术前接受过肝动脉栓塞化疗的肝癌组织中的表达及临床意义
俞武生1, 卢春丽1, 王在国1, 林志强1, 郭荣平2,(), 韦玮2   
  1. 1. 523018 东莞市人民医院肿瘤防治中心肿瘤外科
    2. 中山大学肿瘤防治中心肝胆科,华南肿瘤学国家重点实验室
  • 收稿日期:2010-05-18 出版日期:2010-08-01
  • 通信作者: 郭荣平

Expression and significance of VEGF and MVD in hepatocellular carcinoma patients received preoperative transcatheter arterial embolization

Wu-sheng YU1, Chun-li LU1, Zai-guo WANG1, Zhi-qiang LIN1, Rong-ping GUO2,(), Wei WEI2   

  1. 1. Department of Oncology Surgery, Cancer Ceter, Dongguan People’s Hospitcl, Dongguan 523018, China
  • Received:2010-05-18 Published:2010-08-01
  • Corresponding author: Rong-ping GUO
  • About author:
    Correstonding author: Guo Rong-Ping, Email:
引用本文:

俞武生, 卢春丽, 王在国, 林志强, 郭荣平, 韦玮. VEGF和MVD在术前接受过肝动脉栓塞化疗的肝癌组织中的表达及临床意义[J/OL]. 中华普通外科学文献(电子版), 2010, 04(04): 323-327.

Wu-sheng YU, Chun-li LU, Zai-guo WANG, Zhi-qiang LIN, Rong-ping GUO, Wei WEI. Expression and significance of VEGF and MVD in hepatocellular carcinoma patients received preoperative transcatheter arterial embolization[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2010, 04(04): 323-327.

目的

探讨血管内皮细胞生长因子(VEGF)和平均微血管密度(MVD)在接受术前经导管肝动脉栓塞化疗(TACE)肝癌细胞中的表达和在二期切除肝癌复发预后中的意义。

方法

选取91例术前TACE和50例未行TACE肝癌手术切除标本,采用免疫组化方法检测两组标本VEGF、CD34的表达情况和MVD值。分析两组VEGF的表达情况和MVD值的差异,以及62例术前TACE后根治性切除的肝癌中VEGF的表达水平与复发的关系。

结果

VEGF表达于肝细胞质中,CD34选择性表达于血管内皮细胞,术前TACE组和未行TACE组VEGF的表达(6.9±4.7 vs 5.1±4.4)和MVD值(62.0±35.4 vs 45.6±29.0)差异有统计学意义(P<0.05)。术前TACE后根治性二期切除患者,复发组(45例)与未复发组(17例)肿瘤组织中VEGF阳性率分别为82.2%和41.2%,差异有统计学意义(P<0.05)。VEGF阳性组1、3、5年无瘤生存率分别为50.9%、28.1%、22.5%,VEGF阴性组分别为88.5%、68.2%、53.0%,差异有统计学意义(P<0.05)。多因素分析表明治疗前存在播散结节及VEGF的表达水平是影响TACE后二期切除患者复发的独立危险因素。

结论

TACE后残癌组织血管生成增多,术前TACE后二期根治性切除肝癌VEGF的表达与患者术后复发转移密切相关。

Objective

To study the expression and significance of vascular endothelial growth factor (VEGF) and microvessel density (MVD) in hepatocellular carcinoma (HCC) patients underwent preoperative transcatheter arterial embolization (TACE).

Methods

The expressions of VEGF and CD34 in 91 specimens of HCC with preoperative TACE (TACE group) and 50 specimens of HCC (non-TACE group) were detected by immunohistochemistry method. The expressions of VEGF and CD34 between the two groups were compared. Correlations of VEGF expression to the recurrence were analyzed.

Results

VEGF was expressed in cytolymph and CD34 was expressed in vascular endothelial cell. Expressions of VEGF was significantly higher in TACE group than that in non-TACE group, 6.9±4.7 vs 5.1±4.4, P<0.05, so did MVD, 62.0±35.4 vs 45.6±29.0, P<0.05. In patients who underwent curative resection after preoperative TACE, the positive rates of VEGF were significantly higher in recurrent group than in non-recurrent group, 82.2% vs 41.2%, P<0.05. The 1-, 3-, and 5-year disease-free survival rates in VEGF-negative group were significantly higher than that in VEGF-positive group, 88.5% vs 50.9%, 68.2% vs 28.1%, and 53.0% vs 22.5%, P<0.05. Multivariate analysis revealed that preoperative disseminated nodes and the expression of VEGF were independent recurrence risk factors.

Conclusions

There is more angiogenesis and potentiality of recurrence and metastasis in tumor tissues of HCC patients after TACE. The expression of VEGF is closely correlated to postoperative recurrence of HCC patients who underwent preoperative TACE.

表1 两组临床病理资料的比较[例(%)]
图4 未行TACE组肝癌组织中VEGF的表达情况(×400)
表2 术前接受不同次数TACE的肿瘤标本VEGF表达和MVD值比较(±s
图5 肝癌组织中VEGF不同表达水平组无瘤生存曲线
表3 TACE后二期切除肝癌术后复发的多因素分析
1
Aoki T, Imamura H, Hasegawa K,et al. Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg,2004,139(7):766-774.
2
Aebersold DM, Burri P, Beer KT,et al. Expression of hypoxiainducible factor-1 alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res,2001,61(7):2911-2916.
3
Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score(IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathology,1987,8(3):138-140.
4
Yao DF, Wu XH, Zhu Y,et al. Quantitative analysis of vascular endothelial growth factor,microvascular density and their clinicopathologic features in human hepatocellular carcinoma.Hepatobiliary Pancreat Dis Int,2005,4(2):220.
5
Mitsuhashi N, Shimizu H, Ohtsuka M,et al. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology,2003,37(5):1105-1113.
6
Wada H, Nagano H, Yamamoto H,et al. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int,2006,26(4):414-423.
7
Kim KM, Bse SK, Lee OH,et al.Insulin-like growth factor Ⅱ induced by hypoxia may contribute to angiogenesis of hepatocellular carcinoma. Cancer Res,1998,58(2):348-351.
8
Kobayashi N, Ishii M, Ueno Y,et al. Co-expression of Bcl-2 protein and vascular endothelial growth factor in hepatocellular carcinomas treated by chemoembolization. Liver,1999,19(1):25-28.
9
Aebersold DM, Burri P, Beer KT,et al. Expression of hypoxiainducible factor-1 alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer.Cancer Res,2001,61(7):2911-2916.
10
Lee TK, Man K, Ho JW,et al. FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin Cancer Res,2005,11(23):8458-8466.
11
Guo RP, Zhong C, Shi M,et al. Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. J Cancer Res Clin Oncol,2006,132(9):547-555.
12
郭荣平,钟崇,石明,等.血管内皮生长因子和基质金属蛋白酶-2在肝细胞肝癌中的表达及临床意义.中华肿瘤杂志,2006,28(4):285-288.
13
Iavarone M, Lampertico P, Iannuzzi F,et al. Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma. J Viral Hepat,2007,14(2):133-139.
14
Liu J, Yi J. Relationship between the changes of VEGF level and dendritic cells in peripheral blood of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. J Huazhong Univ Sci Technolog Med Sci,2007,27(1):58-60.
15
Tanaka S, Arii S. Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma. Int J Clin Oncol,2006,11(2):82-89.
[1] 高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[2] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[3] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[4] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[5] 谢田伟, 庞于樊, 吴丽. 超声引导下不同消融术对甲状腺良性结节体积缩减率、复发率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 80-83.
[6] 赖全友, 高远, 汪建林, 屈士斌, 魏丹, 彭伟. 三维重建技术结合腹腔镜精准肝切除术对肝癌患者术后CD4+、CD8+及免疫球蛋白水平的影响[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 651-654.
[7] 李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[8] 司钦亮, 毕世龙, 焦慧骁, 李世照, 陈哲禹, 武玉东. 精索去分化脂肪肉瘤两例并文献复习[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 585-590.
[9] 皮尔地瓦斯·麦麦提玉素甫, 李慧灵, 艾克拜尔·艾力, 李赞林, 王志, 克力木·阿不都热依木. 生物补片修补巨大复发性腹壁切口疝临床疗效分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 624-628.
[10] 公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[11] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[12] 陆镜明, 韩大为, 任耀星, 黄天笑, 向俊西, 张谞丰, 吕毅, 王傅民. 基于术前影像组学的肝内胆管细胞癌淋巴结转移预测的系统性分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 852-858.
[13] 焦振东, 惠鹏, 金上博. 三维可视化结合ICG显像技术在腹腔镜肝切除术治疗复发性肝癌中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 859-864.
[14] 吴雪云, 胡小军, 范应方. 肝切除术中剩余肝再生能力的评估与预测[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 894-897.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要